Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | TP53 wild-type |
Therapy | Adavosertib + PF-00477736 |
Indication/Tumor Type | colon cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | colon cancer | sensitive | Adavosertib + PF-00477736 | Preclinical | Actionable | In a preclinical study, Adavosertib (MK-1775), in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237). | 22713237 |
PubMed Id | Reference Title | Details |
---|---|---|
(22713237) | Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. | Full reference... |